FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224881431> ?p ?o ?g. }

• W4224881431 endingPage "232596712210885" @default.
• W4224881431 startingPage "232596712210885" @default.
• W4224881431 abstract "The efficacy and safety of anti-nerve growth factor (NGF) antibody therapy used for osteoarthritis (OA) pain are controversial.To evaluate the efficacy and safety of anti-NGF antibody therapy via a meta-analysis of randomized controlled trials (RCTs).Systematic review; Level of evidence, 1.PubMed, the Cochrane Central Register of Controlled Trials, Embase, and the Web of Science databases were searched for RCTs assessing anti-NGF antibody treatments for hip and knee OA. A total of 623 records were retrieved from the databases. A random-effects model was used to assess primary and secondary outcomes. Bias was assessed using the Cochrane Collaboration tool, funnel plots, and the Egger test. Subgroup analyses were used to assess the efficacy and safety of the independent variables. Sensitivity analysis was conducted to evaluate the effectiveness of tanezumab and the effectiveness of anti-NGF antibodies compared to active comparator drugs. We present the effects of dose, administration mode, and treatment duration on the efficacy and safety of anti-NGF antibody therapy.There were 19 RCTs included in our meta-analysis. Anti-NGF antibody treatment showed significant improvements on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for pain, physical function, and stiffness as well as on a patient global assessment (PGA). The overall standardized mean differences were as follows: WOMAC pain (-0.31 [95% CI, -0.36 to -0.26]; Z = 11.75; P < .001; I2 = 38%), WOMAC physical function (-0.36 [95% CI, -0.41 to -0.30]; Z = 12.67; P < .001; I2 = 44%), WOMAC stiffness (-3.59 [95% CI, -4.87 to -2.30]; Z = 5.47; P < .001; I2 = 98%), and PGA (-0.28 [95% CI, -0.34 to -0.22]; Z = 9.39; P < .001; I2 = 50%). Anti-NGF antibody treatment resulted in a greater incidence of adverse events (risk ratio, 1.09 [95% CI, 1.06 to 1.12]; Z = 5.60; P < .001; I2 = 0%). The incidence of serious adverse events was similar between the treatment and control groups (risk ratio, 1.15 [95% CI, 0.98 to 1.34]; Z = 1.71; P = .09; I2 = 0%).Anti-NGF antibody treatment significantly relieved pain and improved function in patients with hip and knee OA. However, no conclusion could be drawn regarding the optimal treatment plan for anti-NGF antibodies when all 3 variables (dose, administration mode, and treatment duration) were combined in the analyses." @default.
• W4224881431 created "2022-04-27" @default.
• W4224881431 creator A5019191496 @default.
• W4224881431 creator A5029187240 @default.
• W4224881431 creator A5051779733 @default.
• W4224881431 creator A5059682113 @default.
• W4224881431 creator A5084549887 @default.
• W4224881431 date "2022-04-01" @default.
• W4224881431 modified "2023-09-26" @default.
• W4224881431 title "Efficacy and Safety of Anti–Nerve Growth Factor Antibody Therapy for Hip and Knee Osteoarthritis: A Meta-analysis" @default.
• W4224881431 cites W1567484043 @default.
• W4224881431 cites W1971935688 @default.
• W4224881431 cites W1978358625 @default.
• W4224881431 cites W1983582337 @default.
• W4224881431 cites W1984742195 @default.
• W4224881431 cites W2008442706 @default.
• W4224881431 cites W2028469883 @default.
• W4224881431 cites W2038091223 @default.
• W4224881431 cites W2057093576 @default.
• W4224881431 cites W2060485806 @default.
• W4224881431 cites W2065641030 @default.
• W4224881431 cites W2072869449 @default.
• W4224881431 cites W2081338578 @default.
• W4224881431 cites W2083908960 @default.
• W4224881431 cites W2087455247 @default.
• W4224881431 cites W2097699861 @default.
• W4224881431 cites W2103495251 @default.
• W4224881431 cites W2122341009 @default.
• W4224881431 cites W2123878314 @default.
• W4224881431 cites W2124154423 @default.
• W4224881431 cites W2134905207 @default.
• W4224881431 cites W2157823046 @default.
• W4224881431 cites W2165471060 @default.
• W4224881431 cites W2409479160 @default.
• W4224881431 cites W2411487093 @default.
• W4224881431 cites W2472134474 @default.
• W4224881431 cites W2528385426 @default.
• W4224881431 cites W2562870279 @default.
• W4224881431 cites W2609354761 @default.
• W4224881431 cites W2739254590 @default.
• W4224881431 cites W2782039957 @default.
• W4224881431 cites W2949447363 @default.
• W4224881431 cites W2954490590 @default.
• W4224881431 cites W2966313356 @default.
• W4224881431 cites W3000036091 @default.
• W4224881431 cites W3014194256 @default.
• W4224881431 cites W3040469253 @default.
• W4224881431 cites W3118615836 @default.
• W4224881431 cites W3119762460 @default.
• W4224881431 cites W3126946716 @default.
• W4224881431 cites W3128653999 @default.
• W4224881431 cites W3130991656 @default.
• W4224881431 cites W3138475367 @default.
• W4224881431 cites W4211067786 @default.
• W4224881431 cites W4233138142 @default.
• W4224881431 doi "https://doi.org/10.1177/23259671221088590" @default.
• W4224881431 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35494494" @default.
• W4224881431 hasPublicationYear "2022" @default.
• W4224881431 type Work @default.
• W4224881431 citedByCount "0" @default.
• W4224881431 crossrefType "journal-article" @default.
• W4224881431 hasAuthorship W4224881431A5019191496 @default.
• W4224881431 hasAuthorship W4224881431A5029187240 @default.
• W4224881431 hasAuthorship W4224881431A5051779733 @default.
• W4224881431 hasAuthorship W4224881431A5059682113 @default.
• W4224881431 hasAuthorship W4224881431A5084549887 @default.
• W4224881431 hasBestOaLocation W42248814312 @default.
• W4224881431 hasConcept C126322002 @default.
• W4224881431 hasConcept C142724271 @default.
• W4224881431 hasConcept C168563851 @default.
• W4224881431 hasConcept C1862650 @default.
• W4224881431 hasConcept C187960798 @default.
• W4224881431 hasConcept C204787440 @default.
• W4224881431 hasConcept C2776164576 @default.
• W4224881431 hasConcept C2776478404 @default.
• W4224881431 hasConcept C2779286237 @default.
• W4224881431 hasConcept C2780439572 @default.
• W4224881431 hasConcept C71924100 @default.
• W4224881431 hasConcept C82605166 @default.
• W4224881431 hasConcept C95190672 @default.
• W4224881431 hasConceptScore W4224881431C126322002 @default.
• W4224881431 hasConceptScore W4224881431C142724271 @default.
• W4224881431 hasConceptScore W4224881431C168563851 @default.
• W4224881431 hasConceptScore W4224881431C1862650 @default.
• W4224881431 hasConceptScore W4224881431C187960798 @default.
• W4224881431 hasConceptScore W4224881431C204787440 @default.
• W4224881431 hasConceptScore W4224881431C2776164576 @default.
• W4224881431 hasConceptScore W4224881431C2776478404 @default.
• W4224881431 hasConceptScore W4224881431C2779286237 @default.
• W4224881431 hasConceptScore W4224881431C2780439572 @default.
• W4224881431 hasConceptScore W4224881431C71924100 @default.
• W4224881431 hasConceptScore W4224881431C82605166 @default.
• W4224881431 hasConceptScore W4224881431C95190672 @default.
• W4224881431 hasIssue "4" @default.
• W4224881431 hasLocation W42248814311 @default.
• W4224881431 hasLocation W42248814312 @default.
• W4224881431 hasLocation W42248814313 @default.
• W4224881431 hasOpenAccess W4224881431 @default.

• next